ReviewFrontiers in endocrinology2026
Integrated hormonal, metabolic, and epigenetic regulation of corpus luteum function: insights into steroidogenesis, angiogenesis, and regression.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The corpus luteum is a transient endocrine structure essential for establishing and maintaining early pregnancy, primarily through the secretion of progesterone. Its function is regulated by a complex interplay of hormonal, metabolic, and epigenetic factors that govern steroidogenesis, angiogenesis, and luteal cell fate. Luteotrophic hormones such as luteinizing hormone, prolactin, and prostaglandin E2 promote corpus luteum maintenance by activating key signaling pathways, including cyclic adenosine monophosphate/protein kinase A and mitogen-activated protein kinase, while luteolytic factors such as prostaglandin F2α initiate regression through calcium- and protein kinase C-mediated pathways. Recent studies have highlighted the central roles of metabolic regulators AMP-activated protein kinase and Peroxisome proliferator-activated receptor gamma and the histone methyltransferase Enhancer of zeste homolog 2 in modulating corpus luteum function. These molecules integrate hormonal signals with intracellular energy and lipid status, ultimately influencing gene expression through transcriptional and epigenetic mechanisms. Epigenetic modifications, including DNA methylation, histone acetylation/methylation, and microRNAs, act as dynamic regulators of genes involved in steroid biosynthesis, angiogenesis, and programmed cell death. This review highlights the convergence of hormonal, metabolic, and epigenetic pathways in controlling corpus luteum function and regression, offering new insights into reproductive regulation and therapeutic targets for luteal insufficiency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.